Announcement PDF 605 Page 1 of 3 Form 605 Corporations Act 2001 Section 671B Notice of ceasing to be a substantial holder To Company Name/Scheme Alterity Therapeutics ltd ACN/ARSN/ABN 37 080 699 065 1. Details of substantial holder (1) Name JPMorgan Chase & Co. and its affiliates ACN/ARSN (if applicable) NA The holder ceased to be a substantial holder on 04/February/2025 The previous notice was given to the company on 05/February/2025 The previous notice was dated 03/February/2025 2. Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change Person whose relevant interest changed See Appendix See Appendix See Appendix See Appendix Nature of change (4) Consideration given in relation to change (5) Class (6) and number of securities affected See Appendix 15,480,000 (Ordinary) Person's votes affected J.P. MORGAN SECURITIES LLC Holder of securities subject to an obligation to return under a securities lending agreement J.P. MORGAN SECURITIES LLC Rehypothecation of client securities under a Prime Brokerage Agreement See Appendix 19,512,000 (Ordinary) J.P. MORGAN SECURITIES AUSTRALIA LIMITED Purchase and sales of securities in its capacity as Principal/Proprietary See Appendix 15,029 (Ordinary) 15,029 (Ordinary) J.P. MORGAN PRIME INC. Rehypothecation of client securities under a Prime Brokerage Agreement See Appendix 289,200 (Ordinary) 289,200 (Ordinary) 15,480,000 (Ordinary) 19,512,000 (Ordinary) 3. Changes in association The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable) Nature of association J.P. MORGAN SECURITIES AUSTRALIA LIMITED Subsidiary of JPMorgan Chase & Co. J.P. MORGAN SECURITIES LLC Subsidiary of JPMorgan Chase & Co. J.P. MORGAN PRIME INC. Subsidiary of JPMorgan Chase & Co. 4. Addresses The addresses of persons named in this form are as follows: Name Address JPMorgan Chase & Co. 383 Madison Avenue, New York, New York, NY, 10179, United States J.P. MORGAN SECURITIES AUSTRALIA LIMITED LEVEL 18, 83-85 CASTLEREAGH STREET, SYDNEY, NSW 2000, Australia J.P. MORGAN SECURITIES LLC 383 Madison Ave., New York, New York, NY, 10179, United States J.P. MORGAN PRIME INC. 383 Madison Avenue, New York, New York, NY, 10179, United States 605 Page 2 of 3 Signature Print name Sign here S. Seshagiri Rao Capacity Compliance Officer Date 06/February/2025 605 Page 3 of 3 DIRECTIONS (1) If there are a number of substantial holders with similar or related relevant interests (e.g. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form. (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001. (3) See the definition of "associate" in section 9 of the Corporations Act 2001. (4) Include details of: (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies). See the definition of "relevant agreement" in section 9 of the Corporations Act 2001. (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional n the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired. (6) T he voting shares of a company constitute one class unless divided into separate classes. (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice. TRADES FOR RELEVANT PERIOD Transaction Date Balance at start of relevant period 4-Feb-25 4-Feb-25 4-Feb-25 4-Feb-25 4-Feb-25 4-Feb-25 Balance at end of relevant period Appendix Entity Product Type Type of Transaction J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN PRIME INC. J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED Depository Receipt Depository Receipt Depository Receipt Depository Receipt Depository Receipt Equity Borrow Return Borrow Return Borrow Return On-Lend On-Lend Return Buy Quantity 272,198,215 (600,000) (9,300,000) (5,580,000) 289,200 (19,512,000) 15,029 237,510,444 Price (AUD) 0.01 Consideration $ $ $ $ $ $ 202.89 1/1